Clinical trial NCT02970630: Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study
Official title: Envarsus® Tablets Administered Once Daily in Combination With Everolimus in Elderly De-novo Kidney Transplant Recipients: Open-label, Multicentre, Single-arm, Pharmacokinetic and Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Kidney Transplantation
Keywords: prophylaxis
Lead sponsor: Chiesi Farmaceutici S.p.A.
Sponsor class: INDUSTRY
Collaborators: name: Cromsource
First posted: 2016-11-22
Enrollment: 28
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Prospective, single-arm, open-label, multicentre study with the principal aim to estimate tacrolimus pharmacokinetic parameters in elderly de-novo kidney transplant recipients of ECD (Extended Criteria Donor) kidney grafts treated with Envarsus® prolonged release tablets in combination with everolimus tablets.


Eligibility criteria: Inclusion Criteria:

1. Subject's written informed consent obtained prior to transplant intervention and prior to any study-related procedures;
2. Caucasian male or female subjects aged 60 or older who are receiving a primary or secondary single or dual renal transplant from a blood group compatible deceased donor;
3. Patients who are planned to receive a renal allograft by Extended Criteria Donor (ECD);
4. Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study;
5. Patients with low to standard immunological risk, who had a PRA (Panel Reactive Antibody) ≤ 20% (PRA testing according to centre's practice);
6. Body Mass Index (BMI) between 15 and 35 kg/m2 extremes inclusive;
7. Women must be postmenopausal (physiologic menopause defined as "12 consecutive months of amenorrhea") or permanently sterilized (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) to be enrolled in the study.

Exclusion Criteria:

1. Recipients of any transplanted organ other than a single or dual kidney;
2. Patients unable or unwilling to provide informed consent;
3. Male subjects with females partner of childbearing potential UNLESS they or their partner are willing to use a reliable method of contraception (see below for details) from the time of first dose administration and until 8 weeks after the last dose of study drugs. Male subjects with partners of non-childbearing potential are not required to use contraception.

   Reliable methods of contraception for male subjects and their partner of childbearing potential must be one of the following:
   1. Placement of an intrauterine device or intrauterine system
   2. Hormonal contraception (implantable, patch, oral)
   3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical vaults/caps) with spermicidal foam/gel/film/cream/suppository.
   4. Male sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate "True abstinence" is acceptable only if it is in line with the preferred and usual lifestyle of the subject.
4. Recipients of a bone marrow or stem cell transplant;
5. Recipients of a kidney from a cardiac death donor;
6. Recipients of a kidney from an ABO (0, A and blood cell types) incompatible donor;
7. Recipients having pre-transplant donor specific anti-HLA (Human leukocyte antigen antibodies) (DSA) or who lost the first kidney transplant because of acute rejection;
8. Recipients of a kidney with an anticipated cold ischemia time ≥ 24 hours;
9. Recipients positive for Hepatitis C virus (HCV-RNA positive) and/or Hepatitis B Virus (HBV-DNA or HBsAg positive);
10. Recipients positive for Human Immunodeficiency Virus (HIV-Ab positive);
11. Patients with a current malignancy or a history of malignancy (within the past 5 years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully;
12. Patients with uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives;
13. Patients with severe diarrhoea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of study drugs;
14. Patients with a white blood cell count ≤ 2.8x109/L unless the absolute neutrophil count (ANC) is ≥ 1.0x109/L;
15. Patients with a platelet count ≤ 50.0x109/L;
16. Patients with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) enzyme levels \> 3 times the upper limit of normal during the 30 days prior to the transplant procedure;
17. Patients who were treated with any other investigational agent in the three months prior to enrolment;
18. Patients who received any investigational new drug, or participated in clinical study within the last 8 weeks;
19. Patient planned to receive an induction therapy different from rabbit ATG (Anti-thymocyte globulin) alone or patients who did not start rabbit ATG induction therapy after transplant;
20. Patients who are already on immunosuppressive drugs the day before transplantation, except ATG as per protocol;
21. Patients who are planned to receive therapy with any immunosuppressive agent other than those prescribed in the study;
22. Patients with a known hypersensitivity to corticosteroids, tacrolimus or everolimus or sirolimus or any of the excipients present in study drugs formulations;
23. Patients with hypersensitivity to macrolides;
24. Patients with any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator;
25. Subjects unlikely to comply with the study protocol or unable to understand the nature and scope of the study but also the possible benefits or unwanted effects of the study treatments;
26. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Primary outcomes:
measure: Tacrolimus Area Under the curve at 24 hours (AUC24)
timeFrame: 10 days
measure: Tacrolimus Minimum whole blood concentration (Cmin)
timeFrame: 10 days
measure: Tacrolimus Cmin/daily dose
timeFrame: 10 days
measure: Tacrolimus AUC24/daily dose
timeFrame: 10 days
Secondary outcomes:
measure: Tacrolimus within-patient variability of blood trough level
timeFrame: from day 3 to month 6
measure: Time to reach therapeutic exposure to tacrolimus
timeFrame: from day 3 to month 6
measure: Number of dose adjustments
timeFrame: from day 3 to month 6
measure: Total daily dose
timeFrame: from day 3 to month 6
measure: Renal function using estimated glomerular filtration rate
timeFrame: from day 1 to month 6
measure: Treatment failure rate
timeFrame: from day 1 to month 6
measure: Delayed graft function
timeFrame: from day 1 to month 6
measure: Acute rejection requiring treatment
timeFrame: from day 1 to month 6
measure: Biopsy proven acute rejections
timeFrame: from day 1 to month 6
measure: Tacrolimus Maximum whole blood concentration (Cmax)
timeFrame: 10 days
measure: Tacrolimus Tmax (time that the drug is present at the maximum concentration in serum)
timeFrame: 10 days
measure: Tacrolimus Average whole blood drug concentration (Cave)
timeFrame: 10 days
measure: Tacrolimus % fluctuation
timeFrame: 10 days
measure: Tacrolimus % swing
timeFrame: 10 days
measure: Tacrolimus linear correlation coefficient between Cmin and AUC24
timeFrame: 10 days
measure: Adverse Events
timeFrame: from screening to month 6
measure: Serious Adverse Events
timeFrame: from screening to month 6
measure: Number of opportunistic infections
timeFrame: from screening to month 6
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Ospedale Ca' Granda - Niguarda
city: Milano
country: Italy
facility: Ospedale Maggiore Policlinico
city: Padova
country: Italy
facility: Azienda Ospedaliera di Padova
city: Rome
country: Italy
facility: Policlinico "A. Gemelli"
city: Siena
country: Italy
facility: Policlinico "Le Scotte"
city: Torino
country: Italy
facility: Azienda Ospedaliera S. Giovanni Battista
Study officials:
affiliation: Az Osp Padova, Osp. Civile Padova
name: Paolo Rigotti, MD
role: PRINCIPAL_INVESTIGATOR
References: